NICE will continue to offer joint advice with the Medicines and Healthcare products Regulatory Agenc...
Read moreThe law provides a legal framework for the automatic substitution of biosimilars at the level of the...
Read moreThe deadlock between Vertex and NHS over the cystic fibrosis drug Orkambi was played out in a parlia...
Read moreThe ABPI is working closely with the Department of Health and Social Care, NHS England and NICE to e...
Read moreNICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...
Read moreCanadians pay too much for prescription drugs – and that means far too many go without the medicin...
Read moreSpeaking at the international pharma conference, NICE’s chief executive Sir Andrew Dillon struck a...
Read moreAdults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scot...
Read moreConclusion: Blincyto has significant clinical benefits, but that further evidence on cost-effective...
Read moreNHS England continues to develop its pricing and reimbursement expertise by appointing Blake Dark, a...
Read more